By Rizhlaine F. Posted July 9, 2021 11:35 AM Updated July 9, 2021 11:35 AM
In order to fight against the threat of coronavirus variants, Pfizer-BioNTech is preparing to ask the European Medicines Agency for authorization for the injection of a third dose of vaccine within 6 months of the second.
Never two without three ? While France was experiencing an improvement in the face ofcoronavirus epidemic, the threat of variants risk, once again, of reversing the trend. After the variant Alpha, it’s the turn of the variant Delta to enter the European arena. 60% more transmissible than English strain, this mutant casts the shadow of a fourth wave : it is already at the origin of a rebound of the epidemic in various European countries. It is even on the way to becoming the majority in France.
So to counter this threat, the vaccination massive is at the heart of concerns. But would it be possible to dope thevaccine efficacy current against these mutants? In a press release released Thursday, July 8, 2021, Pfizer-BioNTecha shared his observations on a study examining the effects of third dose which would be administered 6 months after the second injection. According to the first data, this booster dose would allow an efficacy against the virus and its beta variant (South Africa) five to ten times greater than the protection afforded by the first two injections.
About the variant Delta, Pfizer-BioNTech confirms that his vaccine obtains good results against this variant and that a third injection would also strengthen this protection. A study is also underway to confirm this hypothesis. Thus the two companies will make a request to theEuropean Medicines Agencyt to authorize the administration of a third dose within 6 months of the second.